For: |
Khan S, Cameron S, Blaschke M, Moriconi F, Naz N, Amanzada A, Ramadori G, Malik IA. Differential gene expression of chemokines in |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i11/2979.htm |
Number | Citing Articles |
1 |
Yiting Zhang, Linjing Xu, Ling Li. The feasibility of using the compound kushen injection to treat cervical cancer based on network pharmacology and transcriptomics. Medicine 2023; 102(36): e35135 doi: 10.1097/MD.0000000000035135
|
2 |
Shuyi Cen, Kun Liu, Yu Zheng, Jianzhen Shan, Chao Jing, Jiale Gao, Hongming Pan, Zhigang Bai, Zhen Liu. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.705060
|
3 |
Yan Zou, Fengxian Qin, Jifei Chen, Jie Meng, Liuhua Wei, Chunlin Wu, Qiaoyun Zhang, Dong Wei, Xiang Chen, Hao Wu, Xiaoli Chen, Shengming Dai. sTLR4/MD-2 complex inhibits colorectal cancer in vitro and in vivo by targeting LPS. Oncotarget 2016; 7(32): 52032 doi: 10.18632/oncotarget.10496
|
4 |
Juan Garona, Marina Pifano, Giselle Ripoll, Daniel F. Alonso. Vasopressin. Vitamins and Hormones 2020; 113: 259 doi: 10.1016/bs.vh.2019.08.010
|
5 |
Natalia Kuhn, Bertram Klinger, Florian Uhlitz, Anja Sieber, Maria Rivera, Kathleen Klotz-Noack, Iduna Fichtner, Jens Hoffmann, Nils Blüthgen, Christine Falk, Christine Sers, Reinhold Schäfer. Mutation-specific effects of NRAS oncogenes in colorectal cancer cells. Advances in Biological Regulation 2021; 79: 100778 doi: 10.1016/j.jbior.2020.100778
|
6 |
Jun Zeng, Zhong-Hua Tang, Shuang Liu, Shan-Shan Guo. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World Journal of Gastroenterology 2017; 23(10): 1780-1786 doi: 10.3748/wjg.v23.i10.1780
|
7 |
GUIHUA WANG, JIANFEI HUANG, HUIJUN ZHU, SHAOQING JU, HUIMIN WANG, XUDONG WANG. Overexpression of GRO-β is associated with an unfavorable outcome in colorectal cancer. Oncology Letters 2016; 11(4): 2391 doi: 10.3892/ol.2016.4222
|
8 |
Anjong Florence Tikum, Jessica P. Ketchemen, Alireza Doroudi, Anand K. Nambisan, Hanan Babeker, Fabrice Ngoh Njotu, Humphrey Fonge. Effectiveness of225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models. Journal of Nuclear Medicine 2024; 65(3): 402 doi: 10.2967/jnumed.123.266204
|
9 |
Nadia Baartzes, Cristina Szabo, Mihai Cenariu, Florica Imre-Lucaci, Sorin Aurel Dorneanu, Eva Fischer-Fodor, Gregory S. Smith. In vitro antitumour activity of two ferrocenyl metallodendrimers in a colon cancer cell line. Inorganic Chemistry Communications 2018; 98: 75 doi: 10.1016/j.inoche.2018.09.042
|
10 |
Ihtzaz Ahmed Malik, Giuliano Ramadori. Interleukin-6-Production Is Responsible for Induction of Hepatic Synthesis of Several Chemokines as Acute-Phase Mediators in Two Animal Models: Possible Significance for Interpretation of Laboratory Changes in Severely Ill Patients. Biology 2022; 11(3): 470 doi: 10.3390/biology11030470
|
11 |
Anne-France le Rolle, Thang K Chiu, Michael Fara, Jinru Shia, Zhaoshi Zeng, Martin R Weiser, Philip B Paty, Vi K Chiu. The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. Journal of Translational Medicine 2015; 13(1) doi: 10.1186/s12967-015-0555-4
|
12 |
Agnes Ling, Ida V Lundberg, Vincy Eklöf, Maria L Wikberg, Åke Öberg, Sofia Edin, Richard Palmqvist. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. The Journal of Pathology: Clinical Research 2016; 2(1): 21 doi: 10.1002/cjp2.31
|
13 |
Xiaoying Ye, King C. Chan, Andrew M. Waters, Matthew Bess, Adam Harned, Bih-Rong Wei, Jadranka Loncarek, Brian T. Luke, Benjamin C. Orsburn, Bradley D. Hollinger, Robert M. Stephens, Rachel Bagni, Alex Martinko, James A. Wells, Dwight V. Nissley, Frank McCormick, Gordon Whiteley, Josip Blonder. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget 2016; 7(52): 86948 doi: 10.18632/oncotarget.13566
|
14 |
Fenghua Zhang, Jingting Jiang, Bin Xu, Yun Xu, Changping Wu. Over-expression of CXCL2 is associated with poor prognosis in patients with ovarian cancer. Medicine 2021; 100(4): e24125 doi: 10.1097/MD.0000000000024125
|
15 |
Jan Korbecki, Mateusz Bosiacki, Katarzyna Barczak, Ryta Łagocka, Dariusz Chlubek, Irena Baranowska-Bosiacka. The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers. Cells 2023; 12(10): 1406 doi: 10.3390/cells12101406
|
16 |
Camille Ternet, Christina Kiel. Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage. Cell Communication and Signaling 2021; 19(1) doi: 10.1186/s12964-021-00712-3
|
17 |
Juan Garona, Natasha T. Sobol, Marina Pifano, Valeria I. Segatori, Daniel E. Gomez, Giselle V. Ripoll, Daniel F. Alonso. Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer. Cancer Research and Treatment 2019; 51(2): 438 doi: 10.4143/crt.2018.040
|
18 |
JIATENG ZHONG, JINGYU GUO, XINYU ZHANG, SHUANG FENG, WENYU DI, YANLING WANG, HUIFANG ZHU. The remodeling roles of lipid metabolism in colorectal cancer cells and immune microenvironment. Oncology Research 2022; 30(5): 231 doi: 10.32604/or.2022.027900
|
19 |
Simona Delle Monache, Alessio Cortellini, Alessandro Parisi, Fanny Pulcini, Stefano Martellucci, Cecilia Mei, Maria Enrica Danubio, Vincenzo Mattei, Adriano Angelucci, Corrado Ficorella. Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. Journal of Cancer Research and Clinical Oncology 2020; 146(6): 1427 doi: 10.1007/s00432-020-03186-x
|
20 |
Joanna Napp, Paulina Siebel, Hans Rausch, Kenny Kuchta, Thomas Efferth, Frauke Alves, Volker Ellenrieder, Silke Cameron. Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic transplantation pancreatic cancer model. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1454291
|